logo
  

Mitie Buys Privately Held Screening Firm Procius For GBP 2.3 Mln - Quick Facts

Outsourcing company Mitie Group PLC (MTO.L) Thursday announced that it has acquired Procius Limited, a UK pre-employment screening company, from the management team. Consideration of up to 2.3 million pounds is payable, subject to any adjustment for final completion accounts.

Procius is a specialist in pre-employment screening and vetting, and has particular expertise in the aviation and transportation sectors.

Mitie noted that the acquisition will provide its Total Security Management business with additional niche capability and support its growth.

According to the firm, the combined business has over 3,000 customers across all sectors. The acquisition will add an operational hub in Basingstoke to Mitie's PeopleCert and UKCRBs businesses.

Ruby McGregor-Smith CBE, Mitie's Chief Executive, said, "I am delighted to welcome the Procius employees to our rapidly growing screening and vetting business. This acquisition will significantly enhance the services that we offer to our customers, particularly in the aviation and transport sectors."

In London, Mitie shares were losing 0.33 percent, and trading at 273.70 pence.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT